In this edition, FDA approves Vanflyta for newly diagnosed AML; liso-cel could have ‘best shot’ at remission for double refractory CLL; mortality factors among cancer survivors and more. Read the full coverage here:

FDA approves Vanflyta for newly diagnosed acute myeloid leukemia

VIDEO: Liso-cel could have ‘best shot’ at remission for double refractory CLL

Community affluence, insurance mediate CV mortality among Black, white cancer survivors

VIDEO: MOLTO study probes combination therapy in Richter syndrome

Gilead terminates phase 3 trial of magrolimab regimen for myelodysplastic syndrome

References:

ASCO Annual Meeting ASCO Annual Meeting Press Release Press Release Sung H, et al. Int J Epidemiol. 2023;doi:10.1093/ije/dyad097.